DAFNA Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

DAFNA Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-50,000	Closed	-$264K	–	82
2019 Q3	$264K	Hold	50,000	–	–	0.1%	80
2019 Q2	$300K	Hold	50,000	–	–	0.11%	79
2019 Q1	$452K	Hold	50,000	–	–	0.2%	66
2018 Q4	$415K	Buy	+50,000	New	+$512K	0.21%	61
2016 Q3	–	Sell	-2,499	Closed	-$14K	–	82
2016 Q2	$14K	Sell	2,499 -173,733	-99%	-$971K	0.01%	90
2016 Q1	$738K	Buy	+176,232	New	+$847K	0.64%	43
2015 Q2	–	Sell	-35,000	Closed	-$356K	–	76
2015 Q1	$356K	Buy	+35,000	New	+$357K	0.27%	54

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

DAFNA Capital Management's ALDX Position: Q4 2019 in Review

DAFNA Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2019, closing a stake of 50,000 shares — an estimated $264K sold.

DAFNA Capital Management first reported a position in ALDX in Q1 2015 and held it in 7 quarters. The position peaked at $738K in Q1 2016. 77 funds tracked by Wall St. Rank hold ALDX as of Q4 2019.

DAFNA Capital Management reported no remaining Aldeyra Therapeutics position as of Q4 2019 after selling out during the quarter.
DAFNA Capital Management sold 50,000 Aldeyra Therapeutics shares in Q4 2019, an estimated $264K.
DAFNA Capital Management first reported a position in Aldeyra Therapeutics in Q1 2015 and held it in 7 quarters.
DAFNA Capital Management's Aldeyra Therapeutics position peaked at $738K in Q1 2016.
77 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2019.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.